Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...

Cancer cachexia impacts almost 90% of people living with pancreatic cancer. Learn more about this condition in this Q&A with Nicolas Clifford, PanCAN’s manager of research and education communication.

A new phase 2b/3 trial was approved to study of S-pindolol benzoate to treat cachexia, a wasting disease associated with cancer. The Food and Drug Administration (FDA) OKed phase 2b/3 trials to ...

"Cancer-related cachexia and sarcopenia occur in hematologic malignancies, not just gastrointestinal carcinomas and head and neck cancers. Their presence affects all aspects of diagnosis and treatment ...

Cancer cachexia, or the wasting syndrome, is a catastrophic condition that causes dramatic and involuntary loss of muscle mass, fat and weight, alongside extreme fatigue, anorexia and anemia in ...

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

Cancer cachexia is a complex metabolic syndrome characterized by the ongoing loss of skeletal muscle mass, with or without fat loss, that cannot be reversed entirely by conventional nutritional ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and ...

PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

Sept. 14 (UPI) --A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical tests, drugmaker Pfizer announced Saturday. The experimental ...